Current Price and Recent Price Action
The stock closed at ₹830.65 on 14 July 2026, down 0.81% from the previous close of ₹837.40. Intraday volatility saw a high of ₹844.95 and a low of ₹825.25, reflecting cautious trading sentiment. The 52-week price range remains broad, with a high of ₹1,064.70 and a low of ₹635.30, underscoring significant price fluctuations over the past year.
Technical Trend Transition
Technically, Alembic Pharma has shifted from a sideways trend to a mildly bearish one. This transition is corroborated by the daily moving averages, which currently signal a mildly bearish outlook. The stock’s short-term momentum appears to be weakening, although some weekly and monthly indicators present a more nuanced picture.
MACD Analysis
The Moving Average Convergence Divergence (MACD) indicator reveals a divergence in trend signals. On the weekly chart, the MACD remains bullish, suggesting that medium-term momentum retains some upward bias. Conversely, the monthly MACD is bearish, indicating that longer-term momentum is under pressure. This dichotomy suggests that while short to medium-term traders might find some support, the broader trend remains challenged.
RSI and Momentum Oscillators
The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no definitive signal, hovering in neutral zones without indicating overbought or oversold conditions. This lack of directional RSI signal implies that the stock is not exhibiting extreme momentum in either direction, aligning with the overall mixed technical picture.
Bollinger Bands and Volatility
Bollinger Bands analysis adds further complexity. On the weekly scale, the bands suggest a mildly bullish stance, indicating that price volatility is contained and the stock may be poised for a modest upward move. However, the monthly Bollinger Bands are mildly bearish, reflecting longer-term volatility pressures and potential downside risk.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Moving Averages and KST Indicator
Daily moving averages have turned mildly bearish, signalling that short-term price momentum is weakening. This is consistent with the overall shift in trend. The Know Sure Thing (KST) indicator presents a split view: bullish on the weekly timeframe but bearish on the monthly. This suggests that while short-term momentum may still offer some upside potential, the longer-term outlook remains subdued.
Dow Theory and On-Balance Volume (OBV)
According to Dow Theory, the weekly trend shows no clear direction, whereas the monthly trend is mildly bullish. This indicates some underlying strength in the broader market context, though it is not yet reflected in the shorter-term price action. The OBV indicator supports this view, showing no trend on the weekly chart but a bullish signal on the monthly scale, implying accumulation by investors over the longer term.
Comparative Returns and Market Context
Examining Alembic Pharmaceuticals’ returns relative to the Sensex provides further insight. Over the past week, the stock declined by 0.46%, outperforming the Sensex’s 0.85% fall. Over one month, the stock surged 11.78%, significantly ahead of the Sensex’s 2.77% gain. Year-to-date, however, Alembic Pharma has declined 2.07%, while the Sensex fell 8.92%, indicating relative resilience. Over one year, the stock underperformed with a 14.81% loss compared to the Sensex’s 5.92% decline. The three-year return of 27.53% surpasses the Sensex’s 18.39%, but over five years, the stock lagged with a negative 13.94% return against the Sensex’s 47.09%. Over a decade, Alembic Pharma’s 41.28% gain pales in comparison to the Sensex’s 179.04% rise.
Implications for Investors
The mixed technical signals and recent downgrade to a Sell rating by MarketsMOJO, with a Mojo Score of 45.0, suggest caution. The stock’s small-cap status adds to volatility risk, and the mildly bearish technical trend indicates potential near-term weakness. However, the presence of bullish signals on weekly MACD and KST, along with monthly OBV strength, hints at possible accumulation phases and longer-term support.
Alembic Pharmaceuticals Ltd. or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary and Outlook
In summary, Alembic Pharmaceuticals Ltd. is navigating a complex technical environment. The shift to a mildly bearish trend, combined with a downgrade to Sell, signals caution for short-term traders. Yet, the coexistence of bullish weekly indicators and longer-term accumulation signals suggests that the stock may find support if broader market conditions improve. Investors should monitor key technical levels, including the daily moving averages and monthly MACD, for confirmation of trend direction.
Given the stock’s mixed momentum and small-cap volatility, a prudent approach would be to weigh Alembic Pharma’s technical signals alongside fundamental factors and sector dynamics before making investment decisions. The Pharmaceuticals & Biotechnology sector remains competitive and sensitive to regulatory and innovation-driven catalysts, which could influence future price momentum.
Technical Indicator Summary:
- Trend: Sideways to mildly bearish
- MACD: Weekly bullish, Monthly bearish
- RSI: Neutral on weekly and monthly
- Bollinger Bands: Weekly mildly bullish, Monthly mildly bearish
- Moving Averages: Daily mildly bearish
- KST: Weekly bullish, Monthly bearish
- Dow Theory: Weekly no trend, Monthly mildly bullish
- OBV: Weekly no trend, Monthly bullish
Investors should remain vigilant for any shifts in these indicators that could signal a clearer directional move in Alembic Pharmaceuticals Ltd.’s stock price.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
